| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Platelet Activation | 55 | 2023 | 673 | 8.660 |
Why?
|
| Blood Platelets | 78 | 2023 | 2508 | 8.270 |
Why?
|
| Platelet Aggregation | 32 | 2022 | 798 | 3.530 |
Why?
|
| Platelet Function Tests | 26 | 2022 | 270 | 3.440 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 11 | 2018 | 361 | 3.230 |
Why?
|
| Platelet Aggregation Inhibitors | 39 | 2021 | 3068 | 3.170 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 24 | 2021 | 641 | 2.530 |
Why?
|
| Receptors, Purinergic P2Y12 | 12 | 2018 | 132 | 2.270 |
Why?
|
| Ticlopidine | 19 | 2018 | 899 | 2.230 |
Why?
|
| Blood Platelet Disorders | 6 | 2023 | 58 | 2.210 |
Why?
|
| Dinucleoside Phosphates | 6 | 2018 | 74 | 2.180 |
Why?
|
| Flow Cytometry | 31 | 2023 | 5974 | 2.140 |
Why?
|
| Adenosine Diphosphate | 18 | 2016 | 425 | 1.990 |
Why?
|
| P-Selectin | 20 | 2021 | 600 | 1.930 |
Why?
|
| Receptors, Purinergic P2Y1 | 7 | 2018 | 40 | 1.890 |
Why?
|
| Platelet-Rich Plasma | 6 | 2021 | 177 | 1.780 |
Why?
|
| Thiophenes | 12 | 2018 | 588 | 1.610 |
Why?
|
| Hemostasis | 6 | 2023 | 458 | 1.600 |
Why?
|
| Purinergic P2 Receptor Antagonists | 5 | 2013 | 71 | 1.460 |
Why?
|
| Receptor, PAR-1 | 4 | 2021 | 113 | 1.410 |
Why?
|
| Platelet Count | 8 | 2021 | 781 | 1.400 |
Why?
|
| Piperazines | 13 | 2013 | 2488 | 1.280 |
Why?
|
| CD40 Ligand | 8 | 2023 | 526 | 1.210 |
Why?
|
| Aspirin | 16 | 2018 | 3282 | 1.130 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 6 | 2020 | 141 | 1.120 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 5 | 2018 | 233 | 1.090 |
Why?
|
| Anemia, Sickle Cell | 8 | 2021 | 1018 | 1.000 |
Why?
|
| Thrombasthenia | 6 | 2022 | 24 | 0.910 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2013 | 35 | 0.860 |
Why?
|
| Integrin beta3 | 4 | 2018 | 122 | 0.800 |
Why?
|
| Immunoglobulin Fab Fragments | 8 | 2013 | 482 | 0.760 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 495 | 0.740 |
Why?
|
| Blood Coagulation | 11 | 2022 | 1127 | 0.740 |
Why?
|
| Epidermal Growth Factor | 4 | 2021 | 708 | 0.740 |
Why?
|
| Thromboxane B2 | 4 | 2017 | 152 | 0.730 |
Why?
|
| Immunophenotyping | 6 | 2023 | 1880 | 0.720 |
Why?
|
| Electricity | 3 | 2021 | 182 | 0.710 |
Why?
|
| Platelet Membrane Glycoproteins | 16 | 2016 | 293 | 0.680 |
Why?
|
| Drug Resistance | 5 | 2009 | 1609 | 0.650 |
Why?
|
| Hematologic Agents | 1 | 2018 | 39 | 0.650 |
Why?
|
| Megakaryocytes | 2 | 2022 | 545 | 0.630 |
Why?
|
| Cyclooxygenase 1 | 2 | 2009 | 104 | 0.630 |
Why?
|
| Hemorrhage | 7 | 2021 | 3461 | 0.630 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 1179 | 0.620 |
Why?
|
| Dog Diseases | 1 | 2018 | 138 | 0.620 |
Why?
|
| Thrombopoiesis | 1 | 2018 | 153 | 0.590 |
Why?
|
| Platelet Adhesiveness | 8 | 2016 | 161 | 0.570 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 1676 | 0.570 |
Why?
|
| Cell-Derived Microparticles | 4 | 2021 | 168 | 0.520 |
Why?
|
| Acute Coronary Syndrome | 6 | 2018 | 2337 | 0.460 |
Why?
|
| Cytoplasmic Granules | 3 | 2022 | 610 | 0.440 |
Why?
|
| Adenosine | 2 | 2017 | 825 | 0.420 |
Why?
|
| Omeprazole | 1 | 2012 | 112 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 21 | 2013 | 9274 | 0.400 |
Why?
|
| Thiazoles | 1 | 2018 | 1483 | 0.390 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 526 | 0.370 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2009 | 14 | 0.370 |
Why?
|
| Leukocytes | 8 | 2016 | 2043 | 0.360 |
Why?
|
| Liver Diseases | 1 | 2018 | 1253 | 0.360 |
Why?
|
| Receptors, Thrombin | 4 | 2022 | 131 | 0.360 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2021 | 625 | 0.360 |
Why?
|
| Thrombin | 9 | 2021 | 598 | 0.350 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1354 | 0.350 |
Why?
|
| Humans | 124 | 2023 | 744343 | 0.350 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2023 | 131 | 0.350 |
Why?
|
| Pyrazoles | 5 | 2019 | 1972 | 0.320 |
Why?
|
| Communication | 2 | 2022 | 3749 | 0.320 |
Why?
|
| Clot Retraction | 1 | 2007 | 9 | 0.320 |
Why?
|
| Microfilament Proteins | 6 | 2017 | 1152 | 0.310 |
Why?
|
| Cardiology | 1 | 2018 | 1668 | 0.300 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 3768 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2018 | 10943 | 0.290 |
Why?
|
| Factor Va | 2 | 2021 | 10 | 0.290 |
Why?
|
| Arachidonic Acid | 3 | 2006 | 434 | 0.270 |
Why?
|
| Cell Adhesion Molecules | 7 | 2017 | 1602 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 3870 | 0.270 |
Why?
|
| Prodrugs | 1 | 2007 | 268 | 0.270 |
Why?
|
| Cross-Over Studies | 6 | 2017 | 2029 | 0.270 |
Why?
|
| Fibrinogen | 7 | 2006 | 894 | 0.260 |
Why?
|
| Coronary Artery Disease | 8 | 2016 | 6487 | 0.260 |
Why?
|
| Blood Coagulation Factors | 1 | 2007 | 355 | 0.260 |
Why?
|
| Serotonin | 2 | 2021 | 1017 | 0.250 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 257 | 0.240 |
Why?
|
| Dogs | 7 | 2018 | 3912 | 0.240 |
Why?
|
| Double-Blind Method | 12 | 2019 | 12026 | 0.240 |
Why?
|
| Thrombelastography | 3 | 2018 | 164 | 0.230 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 611 | 0.230 |
Why?
|
| Peptides | 4 | 2013 | 4409 | 0.230 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 4328 | 0.220 |
Why?
|
| Cardiovascular Diseases | 8 | 2015 | 15165 | 0.220 |
Why?
|
| Phosphoproteins | 5 | 2017 | 2440 | 0.210 |
Why?
|
| Benzoates | 2 | 2015 | 217 | 0.210 |
Why?
|
| Tyrosine | 3 | 2003 | 1461 | 0.210 |
Why?
|
| Hydrazines | 2 | 2015 | 226 | 0.210 |
Why?
|
| Annexin A5 | 2 | 2015 | 103 | 0.210 |
Why?
|
| Male | 57 | 2021 | 350118 | 0.200 |
Why?
|
| Female | 55 | 2021 | 380194 | 0.200 |
Why?
|
| Eczema | 1 | 2023 | 231 | 0.190 |
Why?
|
| Gaucher Disease | 1 | 2021 | 112 | 0.190 |
Why?
|
| Calgranulin A | 1 | 2021 | 79 | 0.190 |
Why?
|
| Calgranulin B | 1 | 2021 | 84 | 0.190 |
Why?
|
| Kinetics | 7 | 2017 | 6473 | 0.190 |
Why?
|
| Monocytes | 6 | 2015 | 2596 | 0.180 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 462 | 0.180 |
Why?
|
| Middle Aged | 40 | 2021 | 213383 | 0.180 |
Why?
|
| NFATC Transcription Factors | 1 | 2022 | 381 | 0.180 |
Why?
|
| Phenotype | 7 | 2023 | 16365 | 0.170 |
Why?
|
| Electric Stimulation | 2 | 2015 | 1767 | 0.170 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2018 | 50 | 0.170 |
Why?
|
| Fibrinolytic Agents | 4 | 2016 | 2158 | 0.170 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2018 | 53 | 0.160 |
Why?
|
| Case-Control Studies | 10 | 2018 | 21746 | 0.160 |
Why?
|
| Cattle | 7 | 2019 | 3922 | 0.160 |
Why?
|
| Hypothermia, Induced | 1 | 2003 | 752 | 0.160 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 424 | 0.160 |
Why?
|
| Area Under Curve | 2 | 2013 | 1654 | 0.160 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 98 | 0.160 |
Why?
|
| Phosphatidylserines | 3 | 2021 | 193 | 0.160 |
Why?
|
| Adenosine Monophosphate | 2 | 2017 | 275 | 0.160 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 215 | 0.150 |
Why?
|
| Hemophilia A | 1 | 2021 | 351 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2013 | 1460 | 0.150 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 212 | 0.150 |
Why?
|
| Asphyxia | 1 | 2017 | 57 | 0.150 |
Why?
|
| Calpain | 1 | 2017 | 150 | 0.150 |
Why?
|
| Adult | 32 | 2021 | 214055 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 6489 | 0.150 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 712 | 0.140 |
Why?
|
| Pyrimidinones | 1 | 2018 | 371 | 0.140 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 246 | 0.140 |
Why?
|
| Receptors, Purinergic P2X1 | 1 | 2015 | 8 | 0.140 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2015 | 23 | 0.140 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 984 | 0.130 |
Why?
|
| Octoxynol | 1 | 2015 | 77 | 0.130 |
Why?
|
| Thrombosis | 5 | 2016 | 2968 | 0.130 |
Why?
|
| Drug Stability | 1 | 2015 | 291 | 0.130 |
Why?
|
| Gastroparesis | 1 | 2017 | 131 | 0.130 |
Why?
|
| Cell Adhesion | 5 | 2003 | 3144 | 0.130 |
Why?
|
| Antibodies | 2 | 2023 | 2460 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2021 | 1534 | 0.130 |
Why?
|
| Factor V | 2 | 2008 | 178 | 0.120 |
Why?
|
| Sudden Infant Death | 1 | 2017 | 291 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4933 | 0.120 |
Why?
|
| Integrins | 4 | 1993 | 846 | 0.120 |
Why?
|
| Collagen | 5 | 2009 | 2689 | 0.120 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 400 | 0.110 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 498 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2010 | 1873 | 0.110 |
Why?
|
| Drug Monitoring | 3 | 2021 | 956 | 0.110 |
Why?
|
| Stereoisomerism | 1 | 2014 | 624 | 0.110 |
Why?
|
| Time Factors | 9 | 2018 | 40075 | 0.110 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 63 | 0.110 |
Why?
|
| Methionine | 2 | 1986 | 590 | 0.110 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2013 | 1352 | 0.110 |
Why?
|
| Consensus | 1 | 2021 | 2959 | 0.100 |
Why?
|
| Pain | 2 | 2021 | 4986 | 0.100 |
Why?
|
| Peptide Fragments | 7 | 2015 | 5097 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 11725 | 0.100 |
Why?
|
| Reference Values | 2 | 2012 | 4982 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2019 | 63114 | 0.100 |
Why?
|
| Vascular Patency | 3 | 2009 | 886 | 0.100 |
Why?
|
| International Cooperation | 1 | 2018 | 1420 | 0.100 |
Why?
|
| Young Adult | 13 | 2021 | 56430 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 428 | 0.100 |
Why?
|
| Cell Line | 3 | 2016 | 15997 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 976 | 0.100 |
Why?
|
| Light | 2 | 2015 | 1374 | 0.100 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2015 | 372 | 0.100 |
Why?
|
| Thromboxane A2 | 2 | 2008 | 92 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10481 | 0.100 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 3129 | 0.100 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 149 | 0.100 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 209 | 0.100 |
Why?
|
| Neutrophils | 5 | 2022 | 3719 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 1738 | 0.090 |
Why?
|
| Adolescent | 11 | 2021 | 85781 | 0.090 |
Why?
|
| Animals | 27 | 2022 | 168757 | 0.090 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2009 | 7 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 1375 | 0.090 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2009 | 21 | 0.090 |
Why?
|
| Drug Substitution | 1 | 2012 | 281 | 0.090 |
Why?
|
| Diabetic Angiopathies | 2 | 2016 | 818 | 0.090 |
Why?
|
| Parathyroid Hormone | 3 | 1986 | 1801 | 0.090 |
Why?
|
| Aged | 18 | 2019 | 163280 | 0.090 |
Why?
|
| Serotonin Antagonists | 1 | 2009 | 144 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 1157 | 0.080 |
Why?
|
| Thromboplastin | 2 | 2007 | 291 | 0.080 |
Why?
|
| Hydroxyurea | 2 | 2021 | 290 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4456 | 0.080 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 15076 | 0.080 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2007 | 14 | 0.080 |
Why?
|
| Cell Separation | 2 | 2005 | 1751 | 0.080 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 314 | 0.080 |
Why?
|
| Biotransformation | 1 | 2007 | 168 | 0.080 |
Why?
|
| ROC Curve | 1 | 2015 | 3527 | 0.080 |
Why?
|
| Sepsis | 1 | 2022 | 2593 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2019 | 2942 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 19905 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3508 | 0.070 |
Why?
|
| Cystic Fibrosis | 2 | 2007 | 1177 | 0.070 |
Why?
|
| Calcium | 4 | 2021 | 5756 | 0.070 |
Why?
|
| Receptors, Peptide | 1 | 1988 | 272 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 606 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 25043 | 0.070 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2007 | 437 | 0.070 |
Why?
|
| Chest Pain | 1 | 2014 | 1114 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2015 | 11483 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2013 | 8436 | 0.070 |
Why?
|
| Epitopes | 5 | 1992 | 2571 | 0.070 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2006 | 67 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 371 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 3523 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 3386 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2018 | 3743 | 0.070 |
Why?
|
| Morpholines | 1 | 2009 | 571 | 0.070 |
Why?
|
| Glycoproteins | 4 | 2002 | 2263 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2971 | 0.070 |
Why?
|
| Oligopeptides | 5 | 1993 | 1189 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2010 | 599 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5442 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2018 | 41006 | 0.070 |
Why?
|
| Receptors, Immunologic | 2 | 1989 | 1423 | 0.070 |
Why?
|
| Dalteparin | 2 | 2003 | 42 | 0.070 |
Why?
|
| Antigens, Surface | 2 | 1986 | 1663 | 0.060 |
Why?
|
| Wound Healing | 1 | 2016 | 2785 | 0.060 |
Why?
|
| Blood Cells | 1 | 2007 | 309 | 0.060 |
Why?
|
| Cell Communication | 3 | 2022 | 1621 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 3336 | 0.060 |
Why?
|
| Protein Conformation | 5 | 2001 | 4011 | 0.060 |
Why?
|
| Heterozygote | 2 | 2011 | 2804 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2018 | 4599 | 0.060 |
Why?
|
| Benzamides | 1 | 2009 | 1379 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2015 | 4577 | 0.060 |
Why?
|
| Crotalid Venoms | 2 | 1993 | 28 | 0.060 |
Why?
|
| Binding, Competitive | 4 | 2001 | 1157 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2018 | 6544 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2018 | 9146 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2001 | 241 | 0.060 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2006 | 476 | 0.060 |
Why?
|
| Endothelium | 2 | 2003 | 778 | 0.060 |
Why?
|
| Laboratories | 1 | 2007 | 463 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2015 | 9849 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2015 | 3690 | 0.050 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2023 | 160 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2006 | 421 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2013 | 2684 | 0.050 |
Why?
|
| Amino Acid Sequence | 11 | 1992 | 13815 | 0.050 |
Why?
|
| Gene Expression | 1 | 2015 | 7799 | 0.050 |
Why?
|
| Genotype | 5 | 2017 | 12951 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2017 | 23403 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1832 | 0.050 |
Why?
|
| Infant | 3 | 2018 | 35136 | 0.050 |
Why?
|
| Comorbidity | 1 | 2015 | 10388 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2001 | 54 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 996 | 0.050 |
Why?
|
| Protein Binding | 3 | 2002 | 9386 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 11727 | 0.050 |
Why?
|
| Antisickling Agents | 1 | 2021 | 80 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1836 | 0.050 |
Why?
|
| Child | 4 | 2018 | 77709 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3703 | 0.050 |
Why?
|
| Hirudins | 1 | 2001 | 183 | 0.050 |
Why?
|
| Hydrogen Peroxide | 1 | 1984 | 731 | 0.050 |
Why?
|
| Hemostatics | 1 | 2003 | 229 | 0.050 |
Why?
|
| Coronary Disease | 3 | 2005 | 6077 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2021 | 403 | 0.050 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 18029 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 2624 | 0.040 |
Why?
|
| Rats | 3 | 2015 | 24260 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2022 | 356 | 0.040 |
Why?
|
| Hypertension | 1 | 2019 | 8480 | 0.040 |
Why?
|
| Inflammation | 5 | 2022 | 10638 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6538 | 0.040 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 1177 | 0.040 |
Why?
|
| Heparin | 3 | 2003 | 1637 | 0.040 |
Why?
|
| Factor VIII | 1 | 2021 | 347 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2309 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 1572 | 0.040 |
Why?
|
| Recurrence | 2 | 2009 | 8340 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 2161 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2003 | 926 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1813 | 0.040 |
Why?
|
| Epinephrine | 3 | 2008 | 792 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2012 | 675 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2007 | 4217 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 1792 | 0.040 |
Why?
|
| Calcitonin | 4 | 1980 | 336 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 90 | 0.040 |
Why?
|
| Actigraphy | 1 | 2021 | 488 | 0.040 |
Why?
|
| Risk Factors | 4 | 2018 | 72290 | 0.040 |
Why?
|
| Dosage Forms | 1 | 2017 | 56 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1677 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 2538 | 0.040 |
Why?
|
| Ligands | 4 | 1991 | 3282 | 0.040 |
Why?
|
| Binding Sites | 6 | 1993 | 6114 | 0.040 |
Why?
|
| Molecular Sequence Data | 9 | 1992 | 18111 | 0.040 |
Why?
|
| E-Selectin | 1 | 2018 | 579 | 0.040 |
Why?
|
| Edetic Acid | 2 | 2004 | 276 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2014 | 53288 | 0.030 |
Why?
|
| Smoking | 2 | 2013 | 8987 | 0.030 |
Why?
|
| Biological Availability | 1 | 2017 | 397 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 821 | 0.030 |
Why?
|
| Paresis | 1 | 2017 | 179 | 0.030 |
Why?
|
| Cell Division | 2 | 2003 | 4568 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1998 | 281 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2017 | 322 | 0.030 |
Why?
|
| Chromatography, Affinity | 3 | 1992 | 549 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 1970 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 7659 | 0.030 |
Why?
|
| Heredity | 1 | 2015 | 154 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2000 | 7880 | 0.030 |
Why?
|
| Placebos | 1 | 2018 | 1676 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 157 | 0.030 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1993 | 53 | 0.030 |
Why?
|
| Fibrin | 1 | 2016 | 506 | 0.030 |
Why?
|
| Autopsy | 1 | 2017 | 1020 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2007 | 19229 | 0.030 |
Why?
|
| Exocytosis | 1 | 2015 | 353 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 1239 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14722 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8324 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1590 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12245 | 0.030 |
Why?
|
| Coronary Circulation | 2 | 2009 | 1572 | 0.030 |
Why?
|
| Brain Stem | 1 | 2017 | 846 | 0.030 |
Why?
|
| Chymotrypsin | 1 | 1991 | 149 | 0.030 |
Why?
|
| Erythroid Cells | 1 | 2013 | 238 | 0.030 |
Why?
|
| Carbazoles | 1 | 2013 | 226 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2011 | 89 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 1686 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2001 | 4026 | 0.020 |
Why?
|
| United States | 1 | 2018 | 69872 | 0.020 |
Why?
|
| Cell Shape | 1 | 2011 | 375 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2009 | 11 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 528 | 0.020 |
Why?
|
| Cell Membrane | 5 | 2005 | 3748 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2009 | 63 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 636 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 1986 | 2187 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1588 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 629 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 1990 | 263 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 6171 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 12745 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15540 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 166 | 0.020 |
Why?
|
| Temperature | 2 | 2011 | 2206 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 1791 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 89 | 0.020 |
Why?
|
| Behavior | 1 | 2011 | 561 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1990 | 517 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 1213 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 777 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1990 | 1095 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 841 | 0.020 |
Why?
|
| Extracellular Space | 2 | 1986 | 594 | 0.020 |
Why?
|
| Fibronectins | 1 | 1991 | 726 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1990 | 337 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 684 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 738 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2007 | 96 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 2872 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2016 | 2240 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1785 | 0.020 |
Why?
|
| Mice | 3 | 2022 | 81183 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 2007 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2282 | 0.020 |
Why?
|
| Methanol | 1 | 1986 | 85 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2005 | 244 | 0.020 |
Why?
|
| Alprostadil | 1 | 2005 | 89 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2886 | 0.020 |
Why?
|
| Cytoplasm | 2 | 1986 | 1539 | 0.020 |
Why?
|
| Insulin | 1 | 2019 | 6580 | 0.020 |
Why?
|
| Destrin | 1 | 2004 | 9 | 0.020 |
Why?
|
| Blotting, Western | 3 | 2005 | 5179 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 13989 | 0.020 |
Why?
|
| Alleles | 2 | 2013 | 6933 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 2005 | 290 | 0.020 |
Why?
|
| Cyanogen Bromide | 1 | 1984 | 73 | 0.020 |
Why?
|
| Cysteamine | 1 | 1984 | 23 | 0.020 |
Why?
|
| Factor Xa | 1 | 2005 | 162 | 0.020 |
Why?
|
| Cytochalasin D | 1 | 2004 | 92 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1986 | 982 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 8301 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2011 | 1318 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3508 | 0.020 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2004 | 43 | 0.020 |
Why?
|
| Polysomnography | 1 | 2011 | 1776 | 0.020 |
Why?
|
| Amino Acids | 2 | 1992 | 1736 | 0.020 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 112 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 2504 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2011 | 832 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2564 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3479 | 0.010 |
Why?
|
| Ibuprofen | 1 | 2005 | 236 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 2011 | 25625 | 0.010 |
Why?
|
| Species Specificity | 1 | 2007 | 2478 | 0.010 |
Why?
|
| Methods | 1 | 2003 | 1129 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 380 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 1423 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 1085 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14557 | 0.010 |
Why?
|
| Dipeptides | 1 | 2004 | 409 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2170 | 0.010 |
Why?
|
| Atherectomy | 1 | 2001 | 47 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 39050 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 2429 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 9959 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1736 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 391 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 1981 | 186 | 0.010 |
Why?
|
| Kidney | 2 | 2010 | 7186 | 0.010 |
Why?
|
| Platelet Storage Pool Deficiency | 1 | 2000 | 3 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1986 | 2557 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2001 | 214 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1472 | 0.010 |
Why?
|
| Blood | 1 | 2003 | 598 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 253 | 0.010 |
Why?
|
| Vitamin E | 1 | 2005 | 869 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 791 | 0.010 |
Why?
|
| Genome, Human | 1 | 2013 | 4420 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 2003 | 532 | 0.010 |
Why?
|
| Blood Banks | 1 | 2000 | 111 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 21827 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23338 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2001 | 694 | 0.010 |
Why?
|
| Models, Biological | 1 | 2016 | 9583 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2009 | 4199 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 3251 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1981 | 772 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1984 | 3701 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2274 | 0.010 |
Why?
|
| Calibration | 1 | 2000 | 816 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 841 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4751 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 694 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1809 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9727 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 1726 | 0.010 |
Why?
|
| Mutation | 2 | 1992 | 29786 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2011 | 4245 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8554 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 1959 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8642 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12788 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1979 | 2085 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 5615 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2006 | 3107 | 0.010 |
Why?
|
| Radioimmunoassay | 3 | 1980 | 919 | 0.010 |
Why?
|
| Base Sequence | 3 | 1992 | 12797 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 40561 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7149 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17446 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 12720 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13284 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4420 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 29063 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1992 | 6622 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18370 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1991 | 682 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 427 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 13033 | 0.010 |
Why?
|
| Vitronectin | 1 | 1989 | 44 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11366 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 1989 | 52 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1085 | 0.010 |
Why?
|
| CHO Cells | 1 | 1992 | 1406 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 1801 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 1723 | 0.010 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 215 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 2505 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1989 | 829 | 0.000 |
Why?
|
| Cricetinae | 1 | 1992 | 2472 | 0.000 |
Why?
|
| Aspartic Acid | 1 | 1990 | 576 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1990 | 1454 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 57776 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1989 | 2255 | 0.000 |
Why?
|
| Brain Ischemia | 1 | 2000 | 3265 | 0.000 |
Why?
|
| Thyroid Neoplasms | 1 | 1979 | 2282 | 0.000 |
Why?
|
| DNA | 2 | 1992 | 7301 | 0.000 |
Why?
|
| Sialoglycoproteins | 1 | 1986 | 318 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1993 | 2699 | 0.000 |
Why?
|
| Lung Neoplasms | 2 | 1980 | 13102 | 0.000 |
Why?
|
| Pancreas | 1 | 1991 | 1686 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 4186 | 0.000 |
Why?
|
| RNA | 1 | 1992 | 2749 | 0.000 |
Why?
|
| Radioligand Assay | 1 | 1980 | 374 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1987 | 3772 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1979 | 668 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1979 | 2186 | 0.000 |
Why?
|
| Carcinoma | 2 | 1980 | 2375 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1981 | 1801 | 0.000 |
Why?
|
| Parathyroid Glands | 1 | 1978 | 509 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1979 | 420 | 0.000 |
Why?
|
| Retina | 1 | 1986 | 2616 | 0.000 |
Why?
|
| Biological Assay | 1 | 1978 | 652 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1979 | 1276 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1980 | 4034 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1978 | 879 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1979 | 1354 | 0.000 |
Why?
|
| Adenocarcinoma | 2 | 1980 | 6364 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1979 | 4776 | 0.000 |
Why?
|
| Sex Factors | 1 | 1978 | 10397 | 0.000 |
Why?
|
| Aging | 1 | 1978 | 8664 | 0.000 |
Why?
|